Metagenomi (MGX) Projected to Post Earnings on Monday

Metagenomi (NASDAQ:MGX) will likely be issuing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 PM ET.

Metagenomi (NASDAQ:MGX) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The business had revenue of $3.91 million during the quarter, compared to analyst estimates of $7.33 million. Metagenomi had a negative net margin of 348.54% and a negative return on equity of 47.14%. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Metagenomi Stock Down 7.0%

NASDAQ MGX opened at $1.46 on Friday. The stock has a market cap of $54.93 million, a P/E ratio of -0.62 and a beta of 0.45. The company’s 50-day simple moving average is $1.59 and its 200 day simple moving average is $1.92. Metagenomi has a twelve month low of $1.23 and a twelve month high of $3.95.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its holdings in shares of Metagenomi by 276.3% in the fourth quarter. Renaissance Technologies LLC now owns 628,400 shares of the company’s stock valued at $1,018,000 after buying an additional 461,400 shares during the last quarter. Jane Street Group LLC increased its position in Metagenomi by 341.6% in the 4th quarter. Jane Street Group LLC now owns 433,859 shares of the company’s stock valued at $703,000 after acquiring an additional 335,604 shares in the last quarter. Norges Bank acquired a new stake in Metagenomi in the 2nd quarter valued at about $373,000. Bridgeway Capital Management LLC raised its stake in shares of Metagenomi by 102.1% in the fourth quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock worth $641,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of Metagenomi by 1,394.4% in the third quarter. Two Sigma Investments LP now owns 207,528 shares of the company’s stock worth $492,000 after acquiring an additional 193,641 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Metagenomi in a research note on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.